Cloricromen
Chemical compound
- B01AC02 (WHO)
- Ethyl 2-(8-chloro-3-(2-(diethylamino)ethyl)-4-methyl-2-oxo-2H-chromen-7-yloxy)acetate
- 68206-94-0
- 68876
- 62108 Y
- B9454PE93C
- D07139 Y
- ChEMBL255066 Y
- DTXSID2048373
- Interactive image
- O=C(OCC)COc2ccc\1c(OC(=O)/C(=C/1C)CCN(CC)CC)c2Cl
InChI
- InChI=1S/C20H26ClNO5/c1-5-22(6-2)11-10-15-13(4)14-8-9-16(26-12-17(23)25-7-3)18(21)19(14)27-20(15)24/h8-9H,5-7,10-12H2,1-4H3 Y
- Key:GYNNRVJJLAVVTQ-UHFFFAOYSA-N Y
Cloricromen is a platelet aggregation inhibitor.[1]
References
- ^ Orefice G, Grasso A, Fazio N, Del Vecchio G, Volpe G, Coppola M, D'Alessio A, Carrieri PB (1994). "No effect of cloricromen on some coagulation parameters in patients with ischaemic cerebrovascular disease". The Journal of International Medical Research. 22 (5): 287–91. doi:10.1177/030006059402200506. PMID 7867874. S2CID 36081514.
- v
- t
- e
Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)
Glycoprotein IIb/IIIa inhibitors |
|
---|---|
ADP receptor/P2Y12 inhibitors | |
Prostaglandin analogue (PGI2) | |
COX inhibitors | |
Thromboxane inhibitors | |
Phosphodiesterase inhibitors | |
Other |
Vitamin K antagonists (inhibit II, VII, IX, X) | |||||
---|---|---|---|---|---|
Factor Xa inhibitors (with some II inhibition) |
| ||||
Direct thrombin (IIa) inhibitors |
| ||||
Other |
fibrinolytics
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e